Apexigen Announces New Data from Phase 1/2 Trial

https://finance.yahoo.com/news/apexigen-announces-data-phase-1-130000869.html

Apexigen Publicly Listed Post-Business Combination

William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022

2022 SVB Report Results

Devoro Medical Reaches Acquisition Agreement with Boston Scientific!

Apexigen Announces New Data from Phase 1/2 Trial

Luminopia Announces Oversubscribed Seed Extension Round

Apexigen Publicly Listed Post-Business Combination

Skyhawk Collaboration with Sanofi

GrowthCap Top 25 Healthcare Investors - William Dai

William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022

Apexigen to go public via SPAC merger

Huma.AI Series A & Product Update

2022 SVB Report Results

Robert Kamen joins ShangBay Capital as our newest Senior Advisor